Named Bioactive Compounds · Compound
Aesculetin (Coumarin)
Moderate Evidencecompound2 PubMed Studies
Hermetica Superfood Encyclopedia
Aesculetin is a coumarin compound that exhibits antioxidant and anti-inflammatory properties through its hydroxyl group-mediated free radical scavenging mechanisms. This bioactive compound demonstrates hepatoprotective effects by enhancing catalase (CAT) and superoxide dismutase (SOD) enzyme activity.
Aesculetin (6,7-dihydroxycoumarin) is a natural coumarin derivative with the chemical formula C₉H₆O₄, found in plants such as chicory and in traditional Chinese medicine Qinpi from Oleaceae plant bark. It occurs naturally as glycosides like aesculin or caffeic acid conjugates, and can be extracted through hydrolysis or synthesized via condensation of hydroxyhydroquinone triacetate with malic acid.
No human clinical trials, RCTs, or meta-analyses for aesculetin were found in the research dossier. All available evidence comes from preclinical animal models and in vitro studies, with doses of 100-500 mg/kg showing improvements in antioxidant enzyme levels like catalase (CAT) and superoxide dismutase (SOD) in lipid peroxidation models.
No clinically studied human dosage ranges are available as human trials are absent. Preclinical animal studies used 100-500 mg/kg doses for hepatoprotection effects. Consult a healthcare provider before starting any new supplement.
Aesculetin (6,7-dihydroxycoumarin) is a pure phenolic compound (coumarin derivative), not a whole food ingredient, and therefore contains no macronutrients (zero protein, fat, carbohydrates, or dietary fiber) and no conventional micronutrients (vitamins or minerals). Its profile is defined entirely by its bioactive chemistry: Molecular formula C9H6O4, molecular weight 178.14 g/mol, with two adjacent hydroxyl groups at the 6 and 7 positions of the coumarin backbone — the catechol-type arrangement responsible for its primary bioactivities. Typical purity in research/supplemental contexts is ≥98%. Bioactive compound concentration is 100% of the substance by definition as an isolated compound. Preclinical dosing ranges of 100–500 mg/kg (animal studies) provide a reference frame, but no established human dietary intake level exists. Bioavailability data is limited to preclinical models: aesculetin demonstrates moderate oral absorption with first-pass hepatic metabolism; it undergoes glucuronidation and sulfation, producing phase II conjugates that circulate in plasma. Lipophilicity is low (LogP approximately 0.94), limiting passive membrane permeability, though the catechol moiety enhances aqueous solubility (~0.5 mg/mL in water at 25°C). No caloric value is attributable. Co-administration with lipid carriers or piperine may enhance absorption based on structural analogy to related coumarins, but direct bioavailability enhancement data for aesculetin specifically remains limited to in vitro studies.
Aesculetin exerts its antioxidant effects through hydroxyl group-mediated neutralization of free radicals and reactive oxygen species. The compound enhances hepatic antioxidant defense by upregulating catalase (CAT) and superoxide dismutase (SOD) enzymes. Its anti-inflammatory activity involves the reduction of pro-inflammatory markers, though specific pathway inhibition requires further elucidation.
Current evidence for aesculetin is limited to preclinical studies including animal models and in vitro research. Hepatoprotective effects have been demonstrated in animal studies using doses of 100-500 mg/kg, showing significant increases in antioxidant enzyme activity. Antioxidant and anti-inflammatory properties have been observed in laboratory and animal models, but no human clinical trials have been conducted. The therapeutic potential remains promising but requires human studies to establish safety and efficacy profiles.
Safety data for aesculetin in humans is currently unavailable due to the lack of clinical trials. As a coumarin derivative, potential concerns may include hepatotoxicity with prolonged use or high doses, though this has not been specifically documented for aesculetin. Possible interactions with anticoagulant medications should be considered given its coumarin structure. Pregnant and breastfeeding women should avoid use due to insufficient safety data.
